The Use of Alpelisib in Metastatic Estrogen-Receptor-Positive HER2/Neu-Negative Breast Cancer

Abstract

The clinical case presented in the article demonstrates the effectiveness of orange in combination with fulvestrant in metastatic estrogen receptor-positive HER2/neu-negative breast cancer with a mutation in the PIK3CA gene. The resistance of hormone therapy requires the search for new therapeutic options. The results of the SOLAR-1 and BYLieve studies have shown not only the effectiveness of alpelisib, but also new types of toxicity characteristic of this therapy. At the moment, recommendations have been developed for the prevention and treatment of the most frequent adverse events, allowing the drug to be used as safely as possible. With the introduction of alpelisib, the possibilities of non-chemotherapeutic treatment options for prognostically unfavorable patients have not only expanded, but there has also been a trend towards the use of personalized medicine and targeted therapy.